DSO Offers for Virginia Dental Practices in 2026

Key Takeaways for Virginia Dentists

• Competitive DSO offers in Virginia in 2026 often include strong cash at close, balanced equity rollover, and fair earnout terms that usually arise through a structured sell-side process.

• Realistic 2026 multiples range from 5.0x–6.5x EBITDA for single-location practices to 9–11x for multi-location platforms, with specialty practices often receiving higher ranges.

• Typical DSO structures allocate 60–80% cash at close, 15–40% rollover equity, and 5–15% earnouts, so negotiation of each component can be essential before signing a letter of intent (LOI).

• Virginia-specific factors such as Northern Virginia’s payer mix, hygiene revenue, associate depth, and owner concentration can shift multiples by one to two full turns.

• McLerran & Associates runs a competitive 45–60-day bid process that often generates around 10 offers per listing. Request a no-obligation discovery call to see what a competitive process could mean for your outcome.

Current DSO Activity in Virginia in 2026

DSO activity in the Mid-Atlantic has accelerated meaningfully. In Q1 2026, a Northeast-based DSO expanded its Virginia network by partnering with an Arlington-area practice. In May 2026, a 14-location orthodontic group operating across North Carolina and Virginia was sold to a dental platform buyer, and pediatric dentistry groups expanded their presence in Virginia. Regional consolidators are also actively expanding their South and Mid-Atlantic footprints in 2026.

That buyer activity can create real opportunity for Virginia owners, but only when you enter the process with a clear picture of what a competitive offer looks like and the leverage to negotiate it. Understanding how DSOs value practices is the first step in that process.

DSO Multiples for Virginia Practices in 2026

EBITDA, or earnings before interest, taxes, depreciation, and amortization, is the standard profitability measure DSOs use to value practices. The multiple applied to your adjusted EBITDA can be the primary driver of your headline offer. Multiples have moderated from the 13x–16x peak of 2021–2023 but remain attractive as of mid-2026.

Current ranges by practice size and structure, drawn from 2026 market data, can be summarized as follows:

• Established single-location dental practices are valued around 5.0x–6.5x EBITDA in 2026, while smaller owner-dependent ones are discussed around 3.0x–5.0x, down from brief peaks near 7x.

• Practices with $1–3 million in adjusted EBITDA, the classic DSO add-on target, can clear 7–9x, with associate-led structures and strong hygiene programs at the higher end.

• Emerging multi-location platforms with $3–5 million in EBITDA can reach 9–11x from strategic or private equity backed acquirers.

• Specialty practices, including orthodontics, oral surgery, and pediatric dentistry, generally command a meaningful premium over general dentistry ranges, though multiples vary by practice size, payer mix, and buyer competition.

Several factors can move a Virginia practice within or above these ranges. Associate depth, hygiene revenue as a share of collections, payer mix, location within the state, and the presence of a competitive bid process can be some of the main drivers. Owner concentration, where a good chunk of the revenue depends on the owner, can reduce business value.

Cash, Equity, and Earnout Components in DSO Deals

DSO offers are almost never all cash. Typical structures in 2026 include 60–80% cash at closing, 15–40% rollover equity in the acquiring entity, and earnouts as the remaining balance. Clear understanding of each component can be essential before signing a letter of intent (LOI), the binding term sheet that locks in your deal structure.

Structure Type	Cash at Close	Equity Rollover	Earnout
Regional Roll-Up / Add-On	70–80%	15–25%	5–15%
Formal DSO ($500K–$3M EBITDA)	65–75%	20–30%	5–15%
PE-Backed Platform ($3M+ EBITDA)	60–70%	25–35%	5–10%
Joint Venture / Partial Sale	40–60% (on sold stake)	Seller retains minority equity	Varies

Cash at close is the only guaranteed, immediately liquid portion of your proceeds. Rollover equity, your ownership stake in the DSO or its parent platform, in DSO deals is typically illiquid for 5–7 years and converts to cash only when the platform recapitalizes or sells. That equity can multiply in value, often called the second bite of the apple, or underperform if the DSO struggles.

Earnouts are performance-contingent payments, most commonly tied to EBITDA or collections targets over 12–36 months. These payments are made only if those targets are met after you no longer control operations.

Joint Venture vs Total Buyout in DSO Deals

Two broad models dominate DSO affiliation in 2026. In a full buyout, the DSO purchases your practice assets outright. You become an employed clinician under a 3–5 year employment agreement, with compensation typically structured as a percentage of collections.

You receive the highest cash at close of any structure in a full buyout, but your upside is capped. You participate in platform growth only through whatever rollover equity you negotiate.

In a joint venture (JV) or partial-sale structure, the DSO acquires a majority stake, often 51–80%, while you retain a meaningful minority equity position at the practice level. Cash at close on the sold portion typically runs 51–80%, with the seller retaining roughly 20–49% equity that monetizes at the next recapitalization.

JV structures can suit owners who want to continue building value and retain more operational involvement. The trade-off is lower immediate liquidity and a longer time horizon to realize the full economic outcome. The right structure can depend on your age, clinical goals, financial priorities, and how you view the DSO’s trajectory as an investment, because that retained equity functions like a stock position.

Evaluating Whether a DSO Affiliation Fits Your Virginia Practice

For Virginia practices generating $1.5 million or more in revenue, the economic case for a DSO affiliation can be compelling. DSO offers can create a premium over private-buyer valuations on the same practice because institutional buyers often price on EBITDA multiples rather than collections percentages.

The resulting valuation can depend on the specific financial profile of the practice and buyer interest. That premium comes with trade-offs, including a multi-year employment commitment, reduced operational autonomy, and a portion of your proceeds tied to earnouts and illiquid equity.

The total economic outcome, modeled across 3, 5, and 7 years, can matter more than the headline number alone. Whether affiliation feels worth it can depend on your specific practice, your goals, and which buyers are competing for it. A side-by-side comparison of the private-buyer and DSO paths, with real after-tax cash modeled across time horizons, can give you a clearer decision.

Request a side-by-side valuation from McLerran & Associates to see how your Virginia practice may perform across both transition paths.

Key Drivers of Your DSO Multiple in Virginia

Virginia is not a uniform market. Northern Virginia, with its dense, high-income population, strong fee-for-service payer mix, and proximity to major metro demand, can be one of the most attractive markets in the Mid-Atlantic for DSO buyers. Other Virginia markets vary considerably in buyer appetite and achievable multiples.

The factors that can move a Virginia practice within its valuation range include:

• Payer mix: Payer mix is one of the primary valuation levers that shifts multiples within reported bands, with fee-for-service dominant practices at the top of published ranges and Medicaid-heavy practices at the bottom. This factor often sets the ceiling for what other strengths can achieve.

• Hygiene revenue: Hygiene revenue above 30% of collections is tied to premium multiples and stronger DSO offers. Once payer mix sets your baseline, strong recall adherence and healthy hygienist-to-doctor ratios can push you toward the higher end of your range.

• Associate depth: The presence of producing associates can support higher valuation multiples because buyers pay more for collections that transfer cleanly after the sale. Associate coverage can also reduce reliance on the owner.

• Owner production concentration: Practices where the owner generates most clinical revenue face the concentration penalty mentioned earlier, which can reduce offers by 15–40%.

• Location and metro density: Premium dental-practice markets are often consolidated rural states like South Dakota, while most major metros sit near the national 2.5–5x EBITDA benchmark. DSOs, however, tend to concentrate acquisitions in metropolitan areas, so local competition and demographics can shape your range.

• Lease security: Lease terms can affect valuation and the pool of interested buyers, especially remaining term, renewal options, and assignability.

McLerran & Associates’ CPA-led EBITDA analysis reviews every add-back, including above-market owner compensation, personal expenses run through the business, and one-time costs. That work can help create a defensible adjusted EBITDA that shapes the narrative around your profitability before buyers scrutinize it.

Common Red Flags in DSO Offers

Not every DSO offer supports a strong outcome for the seller. Several structural elements in offer language can quietly erode your result:

• Cliff earnouts: These are all-or-nothing payouts that pay nothing if you miss a target by even a small margin. Sellers can negotiate linear, or pro-rata, payouts instead, so a near-miss still pays most of the earnout.

• Undefined overhead allocations: These are post-close corporate overhead charges against your EBITDA for earnout calculation purposes, often for costs you no longer control. Locked-in expense allocations should be negotiated before the LOI is signed.

• Undercapitalized buyers: Cash that was once paid upfront in DSO acquisitions is increasingly being restructured as promissory notes, shifting performance risk back to the selling dentist. A DSO that cannot fund a clean cash-at-close can be a risk to your rollover equity and earnout alike.

• Rollover equity without protections: Rollover equity carries risks of illiquidity, potential forfeiture, dilution from future capital raises, and zero value if the DSO fails to achieve a successful exit. Tag-along rights, anti-dilution provisions, and information rights can often be negotiated.

• Earnout metrics tied to associate retention: Earnouts tied to associate retention can trigger clawbacks or deal collapse if associates depart during the transition period. That risk can increase when the DSO controls the post-close work environment.

How a Sell-Side Advisor Supports Virginia Sellers

A practice owner usually sells once in a career. A DSO negotiates deals every week. That information gap can be the central problem McLerran & Associates aims to solve.

The firm’s process begins with a CPA-led EBITDA analysis, diligence-grade work completed before the practice goes to market. This preparation helps the numbers hold up when buyers scrutinize them so deals are less likely to be renegotiated down later.

From that foundation, McLerran runs a structured, auction-style competitive bid process, typically 45–60 days, among a vetted pool of well-qualified buyers. Poorly run or undercapitalized DSOs are removed from consideration at the outset. The process often generates multiple offers per listing, which can create the competitive tension that pushes price up and terms in the seller’s favor.

For Virginia owners, that process includes a genuine side-by-side comparison of what your practice may be worth in the private-buyer market versus the DSO market. Values are modeled across multiple deal structures and time horizons so you can choose a path with fuller information. McLerran also provides multi-year financial forecasting, quantifying estimated after-tax proceeds across cash, equity, and earnout scenarios, and offers quality-of-earnings support through diligence so the agreed value has a stronger chance of holding when the buyer’s team reviews the details.

The track record behind that process includes approximately 2,000 successful practice sales, roughly $2 billion in closed transaction volume, and a transaction rate of approximately 85–90%, compared to an industry norm closer to 35–40%. McLerran focuses on completing sales, not just listing practices.

Contact Andrew Kobylski’s Northern Virginia team to discuss your practice, your goals, and how a competitive process could shape your outcome.

Conclusion for Virginia Dentists Considering DSOs

Virginia dental practice owners evaluating DSO offers in 2026 are operating in an active buyer market, but active does not always mean equal. Multiples can vary meaningfully by practice size, payer mix, associate structure, and location. Offer structures can be complex, with cash at close, rollover equity, and earnouts each carrying different risk profiles and tax treatment.

The difference between a competitive outcome and a below-market one often comes down to whether you created competition or negotiated with a single buyer. Several key points stand out from this guide:

• Realistic 2026 DSO multiples for Virginia practices can range broadly by size and structure, from the mid-single digits for smaller add-ons to double digits for platform-grade groups, and are driven by fundamentals rather than a fixed table.

• Only the cash-at-close portion of a DSO offer is guaranteed. Earnouts and rollover equity are uncertain and usually require careful negotiation before the LOI is signed.

• Virginia-specific factors, including Northern Virginia’s payer mix and metro density, hygiene revenue, associate depth, and owner production concentration, can move your multiple by one to two full turns.

• A structured, sell-side competitive process can be one of the more reliable ways to improve both price and terms.

To explore what your Virginia practice may be worth in both the private-buyer and DSO markets, and what a competitive process could deliver, call (512) 900-7989, email info@dentaltransitions.com, or contact McLerran & Associates for a confidential conversation.

Frequently Asked Questions

How do I know if my Virginia practice qualifies for a DSO offer?

Most institutional DSO buyers focus on practices generating $1.5 million or more in annual revenue, with an adjusted EBITDA floor that typically starts around $250,000–$300,000. Practices in Northern Virginia with strong fee-for-service payer mix, multiple operatories, associate production, and a transferable patient base tend to attract the broadest buyer interest.

The only reliable way to know where your practice stands is a comprehensive, CPA-led valuation rather than a quick estimate from a buyer. McLerran & Associates evaluates more than 500 practices per year and can explain candidly how your specific practice is positioned in the current market.

What is rollover equity in a DSO deal, and how risky is it?

Rollover equity is the portion of your deal proceeds that you receive as an ownership stake in the DSO or its parent platform rather than as cash. This equity is typically illiquid for several years and converts to cash only when the platform recapitalizes or sells. Its ultimate value depends on how the DSO performs.

If the platform grows and exits at a higher multiple than when you rolled in, your equity can increase significantly. If the DSO underperforms or fails to achieve a favorable exit, that equity may return less than its face value. Because rollover equity can represent 15–35% or more of your total deal value, evaluating the DSO as an investment, including its profitability, management team, private equity backing, and track record, can be as important as negotiating the headline multiple.

McLerran reviews buyers on these criteria and can steer clients away from undercapitalized or poorly run partners.

What is an earnout, and how can I protect myself from a bad one?

An earnout is a contingent payment, typically representing 5–15% of total deal value, that you receive only if your practice hits specified performance targets, usually EBITDA or collections, over a defined period after closing, most commonly 12–24 months. After closing, you no longer control many operational decisions, such as staffing, overhead allocations, scheduling, and marketing, that affect whether those targets are met.

Red flags can include cliff structures, undefined overhead allocations charged against your EBITDA, and earnout metrics tied to factors outside your control. Protections worth considering can include linear, or pro-rata, payouts, locked-in expense definitions, acceleration clauses if the DSO sells during the earnout period, and same-store measurement.

These terms are usually fixed in the letter of intent, which is why pre-LOI negotiation with an experienced sell-side advisor can be critical.

How does a competitive bid process actually increase my valuation?

When a single DSO knows it is your only offer, it has little incentive to improve its terms. When multiple vetted buyers compete simultaneously for your practice, each understands that a below-market offer may lose to a competitor.

That competitive tension can push both price and terms, including more cash at close, better earnout structure, and more favorable equity provisions, in your favor. McLerran’s structured bid process typically runs over a 45–60-day window and narrows to in-person meetings with the top finalists.

Clients who go through a marketed competitive process have historically achieved valuations that can be around 30% higher than owners who sell on their own or negotiate with a single buyer. The process can also surface the full range of buyers in the market, including strategic acquirers who may pay a premium for your specific location or specialty mix, rather than limiting you to whoever reached out first.

Should I sell to a DSO or a private buyer?

The better path can depend on your practice’s size, profitability, and your personal goals. Smaller premier practices, roughly $1–1.5 million in revenue, often fit a doctor-to-doctor sale, where a private buyer pays 100% cash at close with no earnouts or employment commitments.

Larger practices generating $1.5 million or more in revenue are typically DSO-eligible and can command a meaningful premium over what a private buyer, constrained by bank financing, can offer. Practices in the $1.5–3 million revenue range can often go either direction, and the right path can depend on a genuine side-by-side comparison of what each market will pay, after tax, across time.

Because McLerran works both paths in roughly equal measure, the firm prepares that comparison for every client before recommending a direction so you can choose based on real numbers rather than guesswork.